Recruiting × Interventional × Whole-Body Irradiation × Clear all MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Phase 2 Recruiting
132 enrolled
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Phase 2 Recruiting
2,000 enrolled
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Phase 1/2 Recruiting
320 enrolled
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Phase 1/2 Recruiting
260 enrolled
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2 Recruiting
60 enrolled
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Phase NA Recruiting
200 enrolled
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Phase 2 Recruiting
120 enrolled
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Phase 1 Recruiting
16 enrolled
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Phase 1 Recruiting
120 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
ADAPT
Phase 2 Recruiting
60 enrolled
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Phase 2 Recruiting
20 enrolled
CY-MET-RIC
Phase 2 Recruiting
82 enrolled
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Phase 1 Recruiting
155 enrolled
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Phase 2 Recruiting
54 enrolled
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
Phase 1/2 Recruiting
25 enrolled
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Phase 1/2 Recruiting
75 enrolled
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
Phase 1/2 Recruiting
40 enrolled
Personalized NK Cell Therapy in CBT
Phase 2 Recruiting
100 enrolled
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Phase 1/2 Recruiting
36 enrolled
Auto Stem Cell Transplant for Lymphoma Patients
Phase 2 Recruiting
150 enrolled
Two Step Haplo With Radiation Conditioning
Phase 2 Recruiting
63 enrolled
IS-free Treg HaploHCT
Phase 1 Recruiting
30 enrolled
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Phase 1/2 Recruiting
30 enrolled
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Phase 2 Recruiting
68 enrolled
Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 Recruiting
56 enrolled
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Phase 2 Recruiting
20 enrolled
TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT
Phase NA Recruiting
38 enrolled
CARPALL: Immunotherapy with CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
Phase 1 Recruiting
50 enrolled
TESSERACT
Phase 1/2 Recruiting
18 enrolled